ASX Company Announcements

The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange.

 

 20 Dec 2013

 Cleansing Notice and Appendix 3B

 18 Dec 2013

 Results of Completed CK3000 Diagnostic Study

 11 Dec 2013

 $2 Million Capital Raising

 25 Nov 2013

 Change of Director's Interest Notice - Maria Halasz

 25 Nov 2013

 Cleansing Statement

 25 Nov 2013

 Appendix 3B and Change of Interests of Substantial Holding

 22 Nov 2013

 Results of Meeting

 22 Nov 2013

 AGM Presentation by CEO

 20 Nov 2013

 Change in substantial holding

 18 Nov 2013

 Proposed Issue of Shares

 30 Oct 2013

 Release of Shares from Voluntary Escrow

 23 Oct 2013

 Cellmid News

 23 Oct 2013

 Appendix 4C - quarterly

 21 Oct 2013

 Annual Report to Shareholders

 21 Oct 2013

 Notice of Annual General Meeting and Proxy Form

18 Oct 2013

 Key Antibody Patent Granted in Japan

08 Oct 2013

 Key European Patent for Anti-Midkine Antibodies Granted

04 Oct 2013

 R&D Tax refund received

03 Oct 2013

 Midkine antibodies effective in cancer

20 Sept 2013

 Cellmid Signs Major Japanese Distribution Agreement

19 Sept 2013

 Independent Valuation Report of Advangen Inc Japan

18 Sept 2013

 Cellmid CEO Presents at Brokers Meet Biotech

10 Sept 2013

 Date of Annual General Meeting

03 Sept 2013

 Change in substantial holding

28 Aug 2013

 Appendix 4E and Preliminary Final Report

1 Aug 2013

 Cellmid Received Pacific Edge Milestone Shares

29 Jul 2013

 Cellmid Collaborates on Early Diagnosis of Colorectal Cancer

26 Jul 2013

 Appendix 4C - quarterly

22 Jul 2013

 Release of Shares from Voluntary Escrow

18 Jul 2013

 Fujikura Exercises Option To License Cellmid's Diagnostics

16 Jul 2013

 Appointment of Company Secretary

4 Jul 2013

 Change of Director’s Interest Notice

12 Jun 2013

 Change of Director’s Interest Notice

28 May 2013

 Settlement of Advangen Inc Acquisition Completed

20 May 2013

 Cellmid News

08 May 2013

 CEO Presentation

08 May 2013

 Advangen Acquisition

30 Apr 2013

 Change of Company Address

22 Apr 2013

 Appendix 4C - quarterly

08 Apr 2013

 Resignation of Company Secretary

26 Mar 2013

 Cellmid Diagnostic Licenses Update

22 Mar 2013

 Appendix 3B

13 Mar 2013

 Cellmid Completes $2M Placement

 04 Mar 2013

 Change in Director's Interest - M Halasz

19 Feb 2013

 Change in Director's Interest - M Rogers

15 Feb 2013

 Appendix 4D and Half Yearly Accounts

11 Feb 2013

 Cellmid Signs Midkine Diagnostic Agreement

29 Jan 2013

 Cellmid News

29 Jan 2013

 Appendix 4C Quarterly report

23 Jan 2013

 Positive Data in Midkine Antibody Study in Kidney Disease

21 Jan 2013

 European Patent Allowed for Treating Vascular Occlusive Disease

11 Jan 2013

 Change in Director's Interest - M Halasz

07 Jan 2013

 Change in Director's Interest - M Halasz